FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries (collectively "Henlius"), has received approval from the National Medical Products Administration to proceed with a Phase I clinical trial for HLX18, a recombinant anti-PD-1 humanized monoclonal antibody injection, for the treatment of various solid tumors. Henlius intends to conduct the relevant clinical studies in China once the necessary conditions are met.